Trial Profile
A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Roche
- 13 Dec 2022 Results assessing efficacy and safety (At final data cut-off October 21, 2021; safety run-in (N=6), randomized (N=40), and Ext (N=106) cohorts) of single-arm extension cohort study of GO29365 with extended follow-up of up to 5 years, including updated results from the Phase lb safety run-in, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 07 Jun 2022 Results of meta-analysis of 3 randomized controlled trials (NCT01691898, NCT02257567 & NCT03274492) assessing risk of neutropenia and febrile neutropenia associated with use of polatuzumab vedotin for diffuse large B-cell lymphoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 03 Dec 2021 Results assessing the cost-effectiveness of polatuzumab in combination with bendamustine and rituximab (BR) compared to BR in the treatment of patients with diffuse large B-cell lymphoma, in the Portuguese by deriving data from the GO29365, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research